Parkinson’s Disease is often described as a condition where dopamine‑producing neurons slowly die off, but why these neurons are lost has remained one of the biggest unanswered questions in neuroscience. While researchers have long suspected the brain’s immune system plays a role, the exact mechanism has been difficult to pin down.
When we think about Parkinson’s Disease, we often focus on the tremors, stiffness, and slowed movement that shape daily life. But beneath those visible symptoms lies a quieter process: the brain’s struggle to clear out toxic proteins that contribute to neurodegeneration. A newly published study in npj Parkinson’s Disease explores a surprising possible helper in this fight, carbon dioxide, delivered in short, controlled bursts.
Imagine a future where Parkinson’s Disease no longer means a slow decline in movement and independence. Thanks to groundbreaking research and a promising new clinical trial, that future may be closer than you think.
A groundbreaking study from Università Cattolica in Rome and Roma Tre University has identified a key protein, PP2A-B55α (also known as PPP2R2A), as a critical regulator of mitochondrial homeostasis, essentially the balance between clearing out damaged mitochondria and generating new ones. This discovery could open new doors for treating Parkinson’s Disease and other mitochondrial disorders.
Parkinson’s Disease typically begins with subtle symptoms, such as tremors, stiffness, or slowed movement, usually on one side of the body. These signs reflect a brain abnormality affecting mobility, and they tend to worsen over time. The progression varies; some people experience mild symptoms for years, while others face more serious challenges such as difficulty walking, speaking, and even cognitive decline. Parkinson’s affects how individuals engage with the world and can impact their self-confidence. The ultimate goal is to slow or stop the disease’s progression and help patients feel comfortable and true to themselves again.
For over a decade, Carnegie Mellon University neuroscientist Dr. Aryn Gittis has been on a mission to understand how the brain controls movement, a pursuit that is now opening doors to new treatments for Parkinson’s Disease.
